How Will the Market React to Sensus Healthcare Inc (SRTS) Stock Getting a Bullish Rating

Overall market sentiment has been high on Sensus Healthcare Inc (SRTS) stock lately. SRTS receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Sensus Healthcare Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on SRTS!

See Full SRTS Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With SRTS Stock Today?

Sensus Healthcare Inc (SRTS) stock is trading at $4.31 as of 11:00 AM on Monday, Feb 12, a gain of $0.43, or 11.08% from the previous closing price of $3.88. The stock has traded between $4.07 and $4.44 so far today. Volume today is high. So far 343,298 shares have traded compared to average volume of 128,666 shares. To see InvestorsObserver's Sentiment Score for Sensus Healthcare Inc click here.

More About Sensus Healthcare Inc

Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating skin cancers including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated primarily from customers in the United States. Click Here to get the full Stock Report for Sensus Healthcare Inc stock.